SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT, in New York City, New York. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indicationsTreated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune d

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

TD Cowen initiated coverage of Artiva Biotherapeutics with a rating of Buy

Wedbush initiated coverage of Artiva Biotherapeutics with a rating of Outperform and set a new price target of $18.00

Needham initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $23.00